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Abstract
Introduction
Recurrent tuberculosis (TB) is one of the main challenges in TB control. Genotyping based
on Mycobacterial Interspersed Repetitive Units–Variable Tandem Repeats (MIRU-VNTR)
has been widely used to differentiate between relapse and reinfection, which are the two
main causes of recurrent TB. There is a lack of data regarding the causes of TB recurrence
in Georgia, and while differentiating between relapse and reinfection plays a key role in
defining appropriate interventions, the required genotyping methodologies have not been
implemented. The objective of this study was to implement MIRU-VNTR genotyping at the
National Center for Tuberculosis and Lung Diseases (NCTBLD) and differentiate between
relapse and reinfection in multidrug resistant (MDR-) TB patients from Tbilisi, Georgia.
Methods
Recurrent MDR tuberculosis cases from 2014–2016 diagnosed at NCTLD were included in
the study when bacterial samples from both episodes were available. Genotyping based on
the MIRU-VNTR 24 loci was implemented and used for differentiating between relapse and
reinfection. Paired samples showing the same MIRU-VNTR pattern or one locus difference
were classified as relapse, while two and more loci differences were treated as reinfection.
Exact logistic regression was used to identify predictors of recurrence.
Results
Thirty two MDR-TB patients (64 samples) were included and MIRU-VNTR 24 typing was
performed on the corresponding paired samples. Of the 32 patients, 25 (83.3%) were identi-
fied as relapse while 5 (16.7%) were due to re-infection. Patients with a history of incarcera-
tion were significantly associated with TB reinfection (p< 0.05).
Conclusion
Recurrent TB in MDR patients in Georgia are mainly caused by relapse, raising concerns on
the efficacy of the TB control program. An association between incarceration and reinfection
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likely reflects high levels of ongoing TB transmission in prisons, indicating the need for better
TB infection control measures in these settings. Our results add to the rationale for imple-
menting genotypic surveillance of TB more broadly to support TB control in Georgia.
Introduction
Tuberculosis (TB) remains a major global health problem [1]. Recurrent TB, defined as a sec-
ond episode of TB disease in patients previously declared as cured or with successful treatment
completion, contributes to the global burden of TB, and thus needs to be properly addressed if
TB is to be eliminated [1]. Recurrent TB is caused by two fundamentally different mechanisms,
i) relapse caused by the same strains of Mycobacterium tuberculosis and ii) exogenous reinfec-
tion with a different strain [2].
Relapse refers to the reactivation of a subset of bacteria that have not been successfully elim-
inated during patient treatment. The underlying causes of relapse are manifold, and include
various bacterial and host factors [3]. For example, phenotypic drug tolerance in bacterial per-
sisters and differences in pharmaco-genetic characteristics of patients influence to likelihood
of relapse [4,5]. Relapse is thought to be the main contributor to recurrent TB in low incidence
areas [6–8]. In contrast, exogenous reinfection with a distinct M. tuberculosis strain is a partic-
ular problem in high incidence countries [9,10]. In addition, several other risk factors such as
HIV-infection have been associated with recurrent TB disease [10,11]. Understanding the
causes and risk factors driving recurrent TB in a specific epidemiological setting has important
implications for defining adequate control strategies [2].
Georgia, located at the border of Eastern Europe and Western Asia, is a TB middle inci-
dence country with an incidence rate of 84/100,000 per year. Multi-drug resistant / Rifampi-
cin-resistant (MDR/RR) TB patients comprise 11% of all new TB cases and 30% of previously
treated cases, translating into an incidence of MDR/RR TB of 19/100 000. The rate of recurrent
TB cases has been increasing from 10.2 to 15.9 in 2014 and 2017, respectively, mainly due to
lost to follow-up patients, especially for MDR and XDR TB [1]. Despite of an overall decline in
TB incidence from 228/100,000 in 2002 to 84/100,000 in 2018, Georgia remains one of the
high MDR TB burden countries, nowadays showing 56% of successful outcome for 2nd line
treatment [1]. From 2013 until 2016, the proportion of lost to follow-up patients enrolled into
second-line treatment in Georgia has almost halved, from 32% to 18%, but still remains high.
Lost to follow-up patients often suffer from unfavorable outcomes, including a high rate of
recurrent TB [8].
Currently, there is no data on the main causes of recurrent TB in Georgia. Moreover, most
studies on recurrent TB to date in similar settings have only considered small numbers of
drug-resistant patients [6,7,12]. Here we implemented MIRU-VNTR typing in Georgia for the
first time and used this technique to differentiate between the two major causes of recurrent
disease in MDR TB cases in Georgia. We then tested for potential risk factors associated with
either of these two causes of recurrent MDR-TB.
Materials and methods
Data source and study design
In Georgia, the National Tuberculosis Program (NTP), established in 1996, covers the whole
country and includes 64 TB units, 11 microscopy laboratories, and the National Reference
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Laboratory (NRL) at the National Center for Tuberculosis and Lung Diseases (NCTBLD) in
Tbilisi. The NRL is the only laboratory in the country with capacity to perform phenotypic M.
tuberculosis drug susceptibility testing (DST). All TB cases diagnosed by smear microscopy
and/or GeneXpert are sent to the NRL for DST. In addition, the active surveillance of the NTP
in Georgia collects standard epidemiological and clinical information for every suspected TB
case in the country, including from the civil sector and penitentiary system.
For the purpose of this study, we enrolled a retrospective cohort including bacteriologically
confirmed recurrent MDR TB cases recruited between 2014 and 2016. Recurrent TB cases
were identified through the National TB Surveillance electronic database and were classified as
“successfully treated” (including treatment completion) and “lost to follow-up” depending on
the outcome of the primary TB episode. Two cultures per patient and the related patient infor-
mation were included in the study.
Ethics
The study was conducted at the National Reference Laboratory (NRL) in collaboration with
the Swiss Tropical and Public Health Institute. Ethical approval was obtained by the relevant
authorities in Georgia (the Institutional Review Board of the National Center for Tuberculosis
and Lung Diseases, Tbilisi, Georgia) and Switzerland (Ethikkommission Nordwest- und
Zentralschweiz).
Definitions
A case of recurrent TB–was defined as subsequent occurrence of the disease due to relapse or
reinfection, after declaring the patient as clinically cured based on WHO guidelines [1].
Cured–bacteriologically confirmed TB patients were declared as “cured” in case of smear/cul-
ture negative result in at least once or in the last month of the treatment [13]. Lost to follow-
up–patients who did not initiate or interrupted the treatment process for at least two following
months [13]. Relapse–reactivation of endogenous infection that was not eliminated during
treatment of a previous episode of TB [3]. Reinfection–re-occurrence of TB disease caused by
M. tuberculosis strain distinct from the strain that caused the previous episode of TB disease
[3].
Case definition and epidemiological data
Patients were considered eligible for the study in case of recurrent MDR TB episode during
the period 2014–2016, while being declared cured/successfully treated or lost to follow-up for
the first/second TB episode.
Epidemiological data from both episodes was collected, when available. For statistical analy-
sis, epidemiological variables which are biologically plausible potential risk factors for reinfec-
tion or relapse were considered.
Bacteriology
The M. tuberculosis cultures from the primary and secondary episodes, stored at -80˚C, were
obtained from the Georgian NRL isolate collection. Frozen samples were thawed and sub-cul-
tured on Lowenstein-Jensen medium. High quality DNA was extracted using the CTAB
method as described previously [14]. DNA was stored at -20˚C before being used for
genotyping.
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MIRU-VNTR genotyping
Relapse and reinfection were differentiated using MIRU-VNTR genotyping; samples from
both clinical episodes (pairs) were typed using the 24 loci panel as described [15]. Positive and
negative controls were included in each PCR reaction, as H37Rv and H2O, respectively. Dou-
ble allele results were confirmed with two independent PCRs. The 24 loci results were con-
verted into numerical codes based on an allelic table as published by Supply et al [15]. The
24-digit profiles were compared using www.miru-vntrplus.org. Based on the results, each
strain pair was defined as relapse or reinfection. Strain pairs with the same MIRU24 pattern or
one locus of difference were considered as reflecting relapse. MIRU24 patterns differing by
two or more loci between the two strains in a pair were defined as reinfection.
Double alleles in two or more loci were considered mixed infections and excluded from fur-
ther analysis. Cases with double alleles in one locus were attributed to an event of intra-patient
microevolution and considered a case of relapse [3].
Statistical analysis
STATA v14.0 was used for statistical analysis. To compare categorical variables Fisher‘s exact
test was used and quantitative variables were compared using the Wilcoxon rank sum test. In
all statistical comparisons, the significance level was set to 0.05. Logistic regression was used to
assess associations between the odds of relapse / re-infection and the potential predictor vari-
ables gender, age, incarceration status during the primary or recurrent case, smear micros-
copy, HIV, number of people in household and smoking status were considered as
independent variables. These predictor variables were considered one by one, in univariable
models, and upon adjustment for age and imprisonment in multivariable models.
Results
Description of the study population
From a total of 1,361 MDR TB cases enrolled in 2nd-line treatment between 2014 and 2016 in
Georgia, recurrent TB was detected in 485 (35.6%) patients, of whom 245 (50.5%) were suc-
cessfully treated (treatment completed and cured) in the past, and 240 cases (49.5%) were
reported as lost to follow-up. Epidemiological records included information for 40 (16.3%) of
the successfully treated patients (Fig 1). From the total of 40, after exclusion due to missing lab-
oratory data, missing specimen, or sample contamination, we ended up with a complete data
set of 16 MDR-TB patients who were successfully treated (and 32 paired M. tuberculosis iso-
lates). An additional 16 patients from the “lost to follow up” group were randomly selected
and included in the study for comparison. Hence, a total of 32 patients (64 paired samples)
were included in the study (Fig 1).
MIRU-VNTR typing results: Relapse vs. reinfection
Based on our MIRU24 typing results of the 64 paired M. tuberculosis isolates, 25/32 (78.1%)
MDR TB patients had the same genotype in both paired isolates and were classified as relapse,
while 5/32 (15.6%) showed different MIRU patterns and thus evidence of exogenous reinfec-
tion with a different strain. Two patients (6.3%) were classified as harboring a mixed infection.
Comparing patient characteristics across patient groups
After excluding the two patients with mixed infections, further analysis was performed using
clinical and demographical data for the remaining 30 patients (Table 1). The median age of
these patients was 37.5 (Inter Quartile Range (IQR) = 28–43 years) and 41.5 (IQR = 29–47
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years), for the first and recurrent TB episodes, respectively. In the relapse group, the median
age at the first episode was 41 years (IQR = 33–45 years) years and for the recurrent case 44
years (IQR = 35–49 years). In the reinfection group, patients’ median age was 30 years
(IQR = 26–42 years) at the first episode and 32 years (IQR = 28–43 years) at the second (i.e.
reinfection) episode (Table 1). In the civil sector, relapse was observed in 20 (95.2%) patients
out of 21. By contrast in the penitentiary system, 5 (55.6%) out of the 9 patients were due to
relapse, while 4 (44.4%) were due to reinfection (Fisher’s Exact Test, P = 0.004) (Table 1).
Finally, we were interested in the median time to relapse in both groups of patients—suc-
cessfully treated (including treatment completion) and lost to follow-up. The median time
after successful treatment and treatment completion was 49 months (26.7 months; IQR 22.6–
89.4 months), while for the lost-to-follow-up patients, the median period until relapse was, as
expected because of the interruption in treatment, much shorter—17.9 months (20.5 months,
IQR 5.9–56.2 months).
Predictors for TB recurrence
Potential predictors for TB relapse and reinfection were analyzed using logistic regression
(Table 2). Variables were adjusted for age and origin; odds ratios and CI were calculated. Odds
ratios were obtained for lost to follow-up status, smear result, culture conversion, origin,
smoking and number of people in the household, but no variable was statistically significant
except imprisonment with high OR for reinfection (P-value = 0.03) (Table 2).
Discussion
In this study, we used 24 loci based MIRU-VNTR typing to differentiate between relapse and
reinfection in 32 patients with recurrent MDR-TB. Our results showed that the majority
(>95%) of patients with recurrent MDR-TB from the civilian sector were due to relapse,
whereas in patients with a history of incarceration, about half (44%) were due to reinfection.
The differentiation between relapse and reinfection in recurrent TB cases has major impli-
cations for the definition of national control measures. In the case of reinfection, prevention
measures will need to be more inclusive at national level and require reducing TB transmission
along with improving early detection of cases [2,16]. On the other hand, preventing relapse,
Fig 1. Flow diagram of selecting study participants.
https://doi.org/10.1371/journal.pone.0223610.g001
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Table 1. Characteristics of the relapse/reinfection cases defined by MIRU-VNTR typing.
Characteristics Total No. Relapse n (%) Reinfection n (%) P� value
Recurrence 30 25 (83.3) 5 (16.7)
Sex Female
Male
5
25
5 (100)
20 (80)
0
5 (18.5)
0.37
Age at first episode <30
31–40
41–50
>50
11
6
11
2
10 (90.9)
6 (100)
8 (72.7)
1 (50)
1 (9.1)
0
3 (27.3)
1 (50)
0.18
Age at second episode <30
31–40
41–50
>50
9
5
12
4
9 (100)
4 (80)
9 (75)
3 (75)
0
1 (20)
3 (25)
1 (25)
0.28
Group Cured
Lost to follow-up
15
15
11 (73.3)
14 (93.3)
4 (26.7)
1 (6.7)
0.33
Origin Civil
Prison
21
9
20 (95.2)
5 (55.6)
1 (4.8)
4 (44.4)
0.004
Smear a Positive
Discrepant
Negative
Unknown
14
13
2
1
12 (85.7)
10 (76.9)
2 (100)
1 (100)
2 (14.3)
3 (23.1)
0
0
0.75
HIV Positive
Negative
Unknown
1
24
5
1 (100)
21 (87.5)
3 (60)
0
3 (12.5)
2 (40)
0.27
No. of people in household 0–2
3–5
�6
Unknown
6
6
12
6
5 (83.3)
10 (83.3)
5 (83.3)
2 (100)
1 (16.7)
2 (16.7)
1 (16.7)
0
0.57
Smoking Yes
No
16
10
13 (81.2)
9 (90)
3 (18.8)
1 (10)
0.65
�For categorical variables Fisher‘s exact test was used. Quantitative variables were analyzed with Wilcoxon rank sum test.
a Smear results from both episodes were compared, positive indicates Acid Fast Bacilli (AFB) (+) in both samples, discrepant refers to positive and negative results for
either first or second sample, negative was defined with AFB(-) for both episodes.
https://doi.org/10.1371/journal.pone.0223610.t001
Table 2. Potential predictors of TB relapse and reinfection.
Factors associated with relapse
Characteristics N(%)30 Un-adjusted OR (95%CI�) P-value Adjusted OR (95%CI)1 P-value Adjusted OR (95%CI)2 P-value
Lost to follow-up 15(50%) 5.1(52.3–0.5) 0.17 4.1 (44-0-37) 0.25 3.8 (47.9-0-29) 0.31
Smear positive 14(46.7%) 1.4 (9.8–0.2) 0.74 1.1 (8.74–0.15) 0.9 0.4 (5.7–0.03) 0.5
Culture conversion 18(60%) 1 (0.14–7.1) 1 1.21 (9.38–0.16) 0.86 2.86 (39.6–0.21) 0.43
Factors associated with reinfection
Prison 18(60%) 16 (1.45–176.5) 0.02 51.93 (1.43–1891.5) 0.031 NA NA
Smoker 16/26(61.5%) 2.08 (0.18–23.3) 0.55 3.3 (0.23–47.66) 0.38 1.64 (0.11–23.88) 0.72
Household members >2 22/28 (78.6%) 1.11 (0.1–12.31) 0.93 3.32 (0.16–70.11) 0.44 NA NA
�CI = confidence interval
1—Adjusted OR (95%CI) for age
2—Adjusted OR (95%CI) for origin
Lost to follow-up patients, patients with positive smear result and culture conversion were associated with relapse, but neither was statistically significant. While having
been imprisoned, smoking habit and more than two cohabitants were positively associated with re-infection, but only the association with having been imprisoned was
statistically significant.
https://doi.org/10.1371/journal.pone.0223610.t002
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which mostly affects individual patients, requires strengthening treatment adherence in patient
populations at high risk of relapse and more patient-oriented care [17].
Until now, all recurrent TB cases in Georgia were classified as “relapse” by the national sur-
veillance program. This classification, as our data suggests, fails to describe the true nature of
the infection in a substantial proportion of patients. Based on our data, 16.7% of recurrent
cases were due to reinfection, and these were significantly associated with a specific high risk
population, i.e. prisoners. Timely diagnosis of TB disease is a crucial part of controlling TB
transmission in penitentiary system, while delay in diagnosis leads to an increased risk of TB
transmission [18]. Currently, the penitentiary system in Georgia provides an active TB screen-
ing program with questionnaires, followed by Xpert MTB/RIF test in case of disease suspicion.
Regardless of the sharp decrease of TB cases in prison (National Surveillance Program, unpub-
lished data) challenges still arise, in addition to the lack of convenient tools for controlling the
disease [19,20]. Although our study was not directly focusing patients in prisons, our data
shows that reinfection in TB is a significant problem in the penitentiary system that should be
addressed.
Compared to drug susceptible TB, treatment for MDR-TB is long and more complex.
Treatment for such patients includes second-line drugs that are known for their severe toxic
side effects [21]. Increased risk of recurrence due to relapse in MDR-TB patients suggests that
the current MDR-TB treatment might not be enough to completely eliminate the bacteria [22–
24]]. The percentage of MDR-TB cases in previously treated TB patients in Georgia has
increased from 31% in 2010 to 38% in 2016, followed by a decrease to 22% in 2018 (National
Surveillance Program, unpublished data), indicating the presence of a reservoir for drug-resis-
tant bacteria in the country, partially due to incomplete treatment. Surprisingly, we did not
find a statistically significant association between relapse and “lost to follow-up”, but this
could be due to the small sample set included in our study. We found no association between
the number of people in households and risk of reinfection.
We managed to distinguish between relapse and reinfection in most of our cases. However,
reinfection with the same strain of M. tuberculosis might suggest relapse, rendering the differ-
entiation between relapse and reinfection more challenging. While MIRU-VNTR is still a
widely used genotyping tool, whole genome sequencing (WGS) provides higher resolution to
differentiate between closely related Mycobacterium tuberculosis strains. Due to the high costs
and complex data analysis, using WGS is still limited, but gradually becoming more affordable,
and thus likely to replace other genotyping methods in the near future [25].
One of the limitations of the study is the small sample size, leading to the large confidence
intervals in our estimates. However, data from similar incidence settings show similar propor-
tions of relapse and reinfection [9,26–28], and therefore we do not expect these proportions to
change extensively, even if we included a larger sample size.
In conclusion, MIRU-VNTR typing base on 24 loci was implemented successfully in Geor-
gia as a tool for differentiating between recurrent MDRTB caused by relapse versus reinfec-
tion. Our data revealed that relapse is a major contributor to problem of recurrent TB in
Georgia. Despite the recent increases in resources made available to the National Tuberculosis
Program (NTP) to decrease TB incidence countrywide, our data highlights the need for
improved treatment completion and a reduction in the number of patients who were lost to
follow-up.
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